Clinically, mTOR inhibitor everolimus is known to increase progression-free survival when given in combination with exemestane compared to exemestane alone in post-menopausal women with advanced hormone receptor-positive breast cancer [48]; thus, mTOR is a proven target in breast cancer. This evidence concerns the gene MTOR and breast cancer.